PMID- 23668209
OWN - NLM
STAT- MEDLINE
DCOM- 20141103
LR  - 20130514
IS  - 0253-2727 (Print)
IS  - 0253-2727 (Linking)
VI  - 34
IP  - 4
DP  - 2013 Apr
TI  - [Clinical and laboratory features of four cases with IgM multiple myeloma].
PG  - 341-4
LID - 10.3760/cma.j.issn.0253-2727.2013.04.020 [doi]
AB  - OBJECTIVE: To improve the understanding of the clinical and laboratory features 
      of the IgM multiple myeloma (MM). METHODS: The clinical data of four cases of IgM 
      MM patients were collected, their clinical and laboratory features were 
      summarized and analyzed. RESULTS: Four patients met the criteria of IgM MM. They 
      were all male. The age at the diagnosis ranged from 54 to 69 years. The primary 
      symptoms included bone pain, hyperviscosity and bleeding. Three cases had kappa-chain 
      and only one case had lambda-chain. They were all staged ⅢA according to the 
      Durie-Salmon staging system (DSS). One case stagedⅠand three cases staged Ⅱ 
      according to the international staging system (ISS). The average value of IgM, 
      hemoglobin, serum calcium, creatinine and the proportion of bone marrow plasma 
      cells were 83.6 (52.9-111.0) g/L, 79.5 (61.0-105.0) g/L, 3.20(2.11-6.00) mmol/L, 
      104.3 (56.0-171.0) mumol/L and 0.558 (0.290-0.775), respectively. Bone destruction 
      was found in 3 cases. Immunophenotypes of bone marrow plasma cells were analyzed 
      in 3 patients. Results showed that these cells expressed CD38 and CD138, and did 
      not express CD19, CD20 and CD117. Chromosome and fluorescence in situ 
      hybridization (FISH) analysis were carried out in 4 cases and found that all of 
      them had IgH translocations and 1q21 amplification, 2 cases had 13q and 17p 
      deletion, and 3 cases had t(11;14). Three patients received bortezomib-based 
      regimens as induction therapy and reached partial response (PR) - very good 
      partial response (VGPR). Followed up to November 30, 2012, the median 
      progress-free survival (PFS) and overall survival (OS) of the 4 cases were only 
      6.0 (2.5-7.0) months and 17.5 (2.5-27.0) months, respectively. CONCLUSIONS: IgM 
      MM is very rare and is no more than 0.5% in all types of MM. IgM MM have frequent 
      t(11;14) and amp(1q21). Bortezomib-based regimens are effective for it, however, 
      the disease progresses rapidly and has poor prognosis.
FAU - Fan, Jian-ling
AU  - Fan JL
AD  - Department of Hematology, Second Military Medical University, Military Myeloma 
      and Lymphoma Center, Shanghai, China.
FAU - Fu, Wei-jun
AU  - Fu WJ
FAU - Shi, Hao-tian
AU  - Shi HT
FAU - Zhou, Fan
AU  - Zhou F
FAU - Yuan, Zhen-gang
AU  - Yuan ZG
FAU - Zhang, Chun-yang
AU  - Zhang CY
FAU - Wei, Wei
AU  - Wei W
FAU - Ye, Fei
AU  - Ye F
FAU - Zhang, Hui
AU  - Zhang H
FAU - Hou, Jian
AU  - Hou J
LA  - chi
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Immunoglobulin M)
SB  - IM
MH  - Aged
MH  - Humans
MH  - Immunoglobulin M/genetics
MH  - Male
MH  - Middle Aged
MH  - *Multiple Myeloma/drug therapy/genetics
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Translocation, Genetic
EDAT- 2013/05/15 06:00
MHDA- 2014/11/05 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/05/15 06:00 [entrez]
PHST- 2013/05/15 06:00 [pubmed]
PHST- 2014/11/05 06:00 [medline]
AID - 10.3760/cma.j.issn.0253-2727.2013.04.020 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):341-4. doi: 
      10.3760/cma.j.issn.0253-2727.2013.04.020.